Eikon Therapeutics Presents Updated EIK1001 Data at ESMO Congress
The company presented updated data from the TeLuRide-005 study of EIK1001 with pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer.
The company presented updated data from the TeLuRide-005 study of EIK1001 with pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer.